U.S. Capital Wealth Advisors LLC Has $219,000 Stock Holdings in Organon & Co. (NYSE:OGN)

U.S. Capital Wealth Advisors LLC reduced its holdings in shares of Organon & Co. (NYSE:OGN) by 89.6% during the 2nd quarter, Holdings Channel.com reports. The fund owned 10,575 shares of the company’s stock after selling 91,472 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Organon & Co. were worth $219,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Norges Bank bought a new stake in shares of Organon & Co. in the 4th quarter worth about $26,321,000. Sound Shore Management Inc. CT increased its holdings in Organon & Co. by 35.2% during the 4th quarter. Sound Shore Management Inc. CT now owns 4,675,137 shares of the company’s stock valued at $67,415,000 after purchasing an additional 1,216,522 shares in the last quarter. Allianz Asset Management GmbH raised its position in Organon & Co. by 156.5% in the 4th quarter. Allianz Asset Management GmbH now owns 1,900,554 shares of the company’s stock valued at $27,406,000 after purchasing an additional 1,159,519 shares during the last quarter. Kahn Brothers Group Inc. boosted its stake in Organon & Co. by 3,242.4% in the first quarter. Kahn Brothers Group Inc. now owns 1,180,204 shares of the company’s stock worth $22,188,000 after purchasing an additional 1,144,894 shares in the last quarter. Finally, LSV Asset Management grew its holdings in shares of Organon & Co. by 34.0% during the first quarter. LSV Asset Management now owns 4,488,828 shares of the company’s stock worth $84,390,000 after purchasing an additional 1,139,249 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Trading Up 3.0 %

Shares of NYSE:OGN traded up $0.59 during mid-day trading on Friday, reaching $20.15. The stock had a trading volume of 1,676,203 shares, compared to its average volume of 2,287,814. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $23.99. The company has a current ratio of 1.65, a quick ratio of 1.15 and a debt-to-equity ratio of 181.35. The firm has a market cap of $5.18 billion, a PE ratio of 4.93, a price-to-earnings-growth ratio of 1.01 and a beta of 0.85. The firm has a 50 day simple moving average of $20.74 and a two-hundred day simple moving average of $19.31.

Organon & Co. (NYSE:OGN) last posted its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.04. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The firm had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. During the same period in the previous year, the company posted $1.31 earnings per share. The company’s revenue for the quarter was down .1% on a year-over-year basis. On average, research analysts predict that Organon & Co. will post 4.25 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 12th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, August 16th. This represents a $1.12 annualized dividend and a yield of 5.56%. Organon & Co.’s dividend payout ratio (DPR) is currently 27.38%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on OGN. The Goldman Sachs Group increased their price objective on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Piper Sandler boosted their price target on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, April 29th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.